

## Case study

### **Rapid Onset Peripheral Neuropathy in a patient with Amoebic Liver abscess on Metronidazole - A rare complication**

#### **ABSTRACT**

##### **Aim**

We report here a case where the patient developed peripheral neuropathy during a short course of metronidazole treatment at a low cumulative dose which has been rarely reported. This case thus highlights the importance for a treating medical professional to keep in mind that peripheral neuropathy may develop in a patient on metronidazole even on a short duration of it . This peripheral neuropathy is reversible

##### **Presentation of Case**

A 40 year old male patient with no past history of alcohol habit or diabetes was admitted with right side chest pain. Ultrasound and CECT abdomen revealed Amoebic Liver Abscess. He was treated with Metronidazole. After one week of therapy (cumulative dose -16.8 gms) he developed severe burning pain in bilateral lower limbs with NCV study confirming mixed neuropathy. His symptoms resolved after stopping Metronidazole.

##### **Discussion**

The exact mechanism of Metronidazole induced peripheral neuropathy is unknown. It is believed to be secondary to axonal degeneration. It binds to neuronal RNA and inhibits protein synthesis. This results in axonal degeneration .

##### **Conclusion**

Metronidazole is a widely prescribed drug for treatment of amoebic liver abscess . It can cause peripheral neuropathy in patients even on a short course of treatment . Thus it is important to detect this early and discontinue the medication to prevent development of persistent neuropathy .

#### **INTRODUCTION**

Metronidazole is a 5-nitroimidazole derivative. It is generally well tolerated . Its common side effects include mild abdominal pain, headache, nausea and a persistent metallic taste. It may cause peripheral neuropathy at high cumulative doses and during long course treatment (1,2,3,4). We report here a case where the patient developed peripheral

33 neuropathy during a short course of metronidazole treatment at a low cumulative dose  
34 which has been rarely reported.

35

## 36 PRESENTATION OF CASE

37 A 40 year old non diabetic, non smoker and non alcoholic male patient presented with  
38 fever and right sided chest pain for 20 days. Fever was of high grade, intermittent type and  
39 associated with chills and rigors. There was history of right sided chest pain which was dull  
40 in nature .There was decrease in appetite. There was no past history of hypertension or  
41 tuberculosis.

42 On examination, liver was enlarged (span 18 cm) and tender without ascites. Breath  
43 sounds, Vocal fremitus and Vocal resonance were decreased on right side of thorax.  
44 Percussion note was dull in right lower chest. Rest of the systemic examination was normal.  
45 On Investigation - Complete Blood Count levels were normal except for TLC - 19,700/ul .  
46 KFT and LFT were within normal limits. USG whole abdomen showed a well defined  
47 hypoechoic lesion of size 8.3\*7.8\*7.2 cm in segment VIII of liver without vascularity  
48 suggestive of liver abscess. CECT chest and whole abdomen study revealed a large  
49 capsulated thick walled rim enhancing fluid density lesion of size 9.7\*7.6\*9.6 cm in right  
50 lobe of liver predominantly involving segment VIII. The medial wall had discontinuity  
51 suggesting intra pleural rupture and right sided pleural effusion. Amoebic Serology IgG  
52 levels were - 6.07 (positive being level > 1.1). Diagnosis of Amoebic Liver Abscess was made.  
53 He was started on Ceftriaxone and Metronidazole for treatment. An Inter costal tube was  
54 placed for drainage of pus from pleural space. The patient started showing improvement in  
55 all symptoms after starting treatment.His lab reports also improved ( TLC- 8900/ul after 7  
56 days of treatment). He complained of new onset burning sensation in bilateral lower limbs  
57 after 7 days of treatment which worsened over the next 2 days. Neurological examination  
58 showed loss of all sensory modalities in bilateral lower limbs . Serum levels of Vitamin B12  
59 and Thyroid Function Test were within normal range. Nerve conduction velocity (NCV) study  
60 was done which showed evidence of mixed neuropathy affecting the lower limbs and  
61 suggesting axonal neuropathy. Diagnosis of peripheral neuropathy was made. After  
62 excluding all other causes of peripheral neuropathy, metronidazole was considered to be  
63 responsible for it . Metronidazole was thus stopped. The patient's peripheral neuropathy  
64 symptoms improved after metronidazole was stopped and completely resolved after 3  
65 weeks of stopping it.

66

67

## 68 CONCLUSION

69 The Patient 's clinical features of Peripheral neuropathy was diagnosed to caused by Metronidazole  
70 and was treated by stopping Metronidazole .

71

## 72 **DISCUSSION**

73 Metronidazole is commonly used drug to treat anaerobic and amoebic infection. It is usually  
74 well tolerated, but prolonged use of this drug is associated with peripheral neuropathy . The exact  
75 mechanism of Metronidazole induced peripheral neuropathy is unknown.In experimental  
76 models, metronidazole or its metabolites were found to bind selectively withneuronal  
77 ribonucleic acid (RNA) . After binding, they inhibit protein synthesis and result in axonal  
78 degeneration(4,5) .Other suggested mechanisms include the following : modulation of  
79 gamma-amino butyric acid (GABA) by intermediate metabolite of metronidazole in the  
80 central nervous system ,or free radical injury to nerve tissue (4,6) .

81 The overall incidence of metronidazole associated peripheral neuropathy is unknown . On  
82 reviewing the literature , most cases of metronidazole associated peripheral neuropathy  
83 are seen with >42 g of total drug or >4 weeks of treatment as compared to those patients  
84 receiving  $\leq$ 42 g total (17.9% vs. 1.7%) (1). Symptoms resolve after discontinuation of therapy  
85 in most patients . The treating medical professional should thus keep in mind that  
86 peripheral neuropathy may develop in a patient on metronidazole even on a short duration  
87 of it .

88

## 89 **ACKNOWLEDGEMENTS**

90 We acknowledge the support of staff in departments of internal medicine and radiology .

91

92

## 93 **COMPETING INTEREST**

94 All authors declare that there were no conflicts of interest.

95

96

97

## 98 **CONSENT**

99 Written Informed consent was obtained from the patient for this case report

100

101 **REFERENCES**

- 102 1. Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the  
103 literature . Goolsby TA (1), Jakeman B (2) , Gaynes RP (3). Int J Antimicrob Agents . 2018  
104 Mar;51(3):319-325. doi:10.1016/j.ijantimicag.2017.08.033. Epub 2017 Sep 5
- 105 2. Gupta B S, Baldwa S, Verma S, Gupta J B, Singhal A. Metronidazole induced neuropathy.  
106 Neurol India 2000;48:192
- 107 3. A Case Report of Metronidazole-Induced Central Nervous System Complications (P4.396)  
108 Ning Wu, Joseph Nguyen, Aiesha Ahmed  
109 Neurology Apr 2016, 86 (16 Supplement) P4.396  
110
- 111 4. Rapid onset peripheral neuropathy:A rare complication of metronidazoleHitender  
112 KumarAsha Sharma,SK Attri ,Sumin Kaushik  
113 JIACM 2012;13(4):346-8  
114
- 115 5. Bradley WG,Karlsson IJ,Rassol CG. Metronidazole neurophy. BrMed J (Clin Res)1977; 2:  
116 610-11.
- 117 6. Rao DN,Mason RP. Generation of nitro radical anions of some 5-nitrofurans 2-and 5-  
118 nitroimidazoles by norepinephrine, dopamineand serotonin:A possible mechanism for  
119 neurotoxicity caused bynitroheterocyclic drugs. J Biol Chem 1987;262:1173-6.

120

121

122

123

124

125

126

127

128

129

130

131

132